4.5 Article

Recurrence patterns and impact of brain metastases in synchronous single organ oligometastatic lung cancer following local ablative treatment-A multicenter analysis

Journal

LUNG CANCER
Volume 170, Issue -, Pages 165-175

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2022.06.017

Keywords

Oligometastatic disease; Local ablative treatment; Non-small cell lung cancer; Brain metastases

Ask authors/readers for more resources

This study conducted a multicenter analysis on patients with oligometastatic lung cancer and found that controlling brain metastasis played a crucial role, and repeated local ablative therapy can effectively prolong the survival time.
Introduction: Local ablative therapy (LAT) improves survival in oligometastatic lung cancer (OMD), but there is limited information on recurrence patterns, re-treatments and in particular the role of brain metastases during the course of disease. We therefore conducted a retrospective multicenter analysis to evaluate course of disease, sequence of therapies and predictors for long-term disease-control in the brain and survival endpoints. Patients and methods: Clinical data of patients with synchronous, single organ OMD with <= 4 metastases were collected from 5 certified German lung cancer centers. All patients underwent thorough initial staging including a (18)FDG-PET/CT scan, brain imaging and mediastinal staging, if necessary, and received LAT to all sites of disease. Results: In total, 164 patients were included (median age 62 years [range 41-84], non-squamous histology 80%, N0-1 64%, single metastasis 84%), 103 had brain (cohort A), 61 extracranial metastases (cohort B). With a median follow-up of 66 months, 115 patients (70%) experienced recurrent disease with a different distribution of sites: In cohort A vs. B, brain relapses occurred in 56% vs. 18% and new distant metastases in 5% vs. 40%. In total, LAT for every relapse was possible for 25% (29/115) of the patients. Patients with initial and secondary onset brain metastases experienced long-term disease-control in the brain and subsequently favorable survival with the application of repeated LAT (disease in the brain controlled vs. not-controlled, HR 0.21, p < 0.001). Comparable long-term overall survival was observed in patients with no or isolated brain relapses (5-years OS 74% and 92%) in contrast to patients with extracranial relapses (5-years OS 19.6%, p < 0.001). Conclusions: Repeated LAT for recurrent synchronous single organ OMD results in a long-term favorable outcome. Disease control in the brain appears crucial and likely determines survival.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available